Stock Events

Stock Events

Cardiff Oncology 

€1.29
63
-€0.04-3.24% Today

Statistics

Day High
1.29
Day Low
1.29
52W High
3.76
52W Low
1.24
Volume
-
Avg. Volume
-
Mkt Cap
86.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.27
-0.22
-0.16
-0.11
Expected EPS
-0.134825
Actual EPS
N/A

Financials

-6,658.92%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.3MRevenue
-86.24MNet Income

Analyst Ratings

$7.59Average Price Target
The highest estimate is 7.59.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XE7C.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including targeted therapies and immunotherapies that compete across multiple areas of cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb offers a wide range of cancer treatments, including targeted therapies and immunotherapies, directly competing with Cardiff Oncology's approach to cancer treatment.
Merck
MRK
Mkt Cap298.84B
Merck is known for its strong oncology pipeline, including blockbuster cancer drug Keytruda, competing in the space of innovative cancer therapies.
AMGEN
AMGN
Mkt Cap187.56B
Amgen has a diverse oncology portfolio, including treatments for solid tumors and hematologic malignancies, making it a competitor in the broader oncology market.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its acquisition of Kite Pharma, has become a leader in cell therapy for cancer, competing in the innovative treatment space alongside Cardiff Oncology.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad oncology portfolio, including targeted therapies and immunotherapies, competing in various cancer treatment areas.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie, with its acquisition of Pharmacyclics, has strengthened its oncology portfolio, competing in the space of cancer treatment with a focus on hematologic malignancies.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, known for its innovative biologics, competes in the oncology space with treatments that could potentially overlap with Cardiff Oncology's target patient populations.

About

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Mani Mohindru Ph.D.
Employees
30
Country
DE
ISIN
US14147L1089
WKN
000A2P4GU

Listings

XNAS
US
CRDF
F
DE
XE7C.F
BOATS
BOATS
CRDF.BOATS

0 Comments

Share your thoughts

FAQ

What is Cardiff Oncology stock price today?▼
The current price of XE7C.F is €1.29 EUR — it has decreased by -3.24% in the past 24 hours. Watch Cardiff Oncology stock price performance more closely on the chart.
What is Cardiff Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cardiff Oncology stocks are traded under the ticker XE7C.F.
Is Cardiff Oncology stock price growing?▼
XE7C.F stock has fallen by -2.72% compared to the previous week, the month change is a -16.17% fall, over the last year Cardiff Oncology has showed a -46.75% decrease.
What is Cardiff Oncology market cap?▼
Today Cardiff Oncology has the market capitalization of 86.62M
When is the next Cardiff Oncology earnings date?▼
Cardiff Oncology is going to release the next earnings report on April 30, 2026.
What were Cardiff Oncology earnings last quarter?▼
XE7C.F earnings for the last quarter are -0.09 EUR per share, whereas the estimation was -0.16 EUR resulting in a +41.8% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cardiff Oncology revenue for the last year?▼
Cardiff Oncology revenue for the last year amounts to 1.3M EUR.
What is Cardiff Oncology net income for the last year?▼
XE7C.F net income for the last year is -86.24M EUR.
How many employees does Cardiff Oncology have?▼
As of April 08, 2026, the company has 30 employees.
In which sector is Cardiff Oncology located?▼
Cardiff Oncology operates in the Health Care sector.
When did Cardiff Oncology complete a stock split?▼
The last stock split for Cardiff Oncology was on February 21, 2019 with a ratio of 1:6.
Where is Cardiff Oncology headquartered?▼
Cardiff Oncology is headquartered in San Diego, DE.